Navigation Links
Replidyne and Cardiovascular Systems Sign Merger Agreement
Date:11/4/2008

tunities across the life sciences, molecular diagnostics and medical device industries. After assessing the merger with CSI, we were impressed by the strong launch of the Diamondback 360 degrees(TM), the growth opportunity for treatment of peripheral arterial disease with this product, particularly in calcified lesions, and the quality of the management team driving the company."

The boards of directors of both Replidyne and CSI have unanimously approved the transaction, which is subject to customary closing conditions, including approval by the shareholders of each of Replidyne and CSI. The merger agreement contains certain termination rights for both Replidyne and CSI. The directors, as well as certain significant shareholders, of each of Replidyne and CSI have executed voting agreements in favor of the transaction.

The transaction is expected to close during the first calendar quarter of 2009. Upon consummation of the merger, Replidyne's name will be changed to Cardiovascular Systems, Inc. and the combined company will apply for listing on The NASDAQ Global Market(R) under a new trading symbol.

CSI had filed for an initial public offering in January 2008, but withdrew its registration statement for the initial public offering today. According to Martin, "The current equity market conditions have resulted in the IPO market coming to a standstill. Given the uncertainty regarding timing of a market recovery, we believe that this transaction offers the best opportunity at this time for continued growth and for our company to gain access to the public capital markets."

Morgan Stanley acted as financial advisor to Replidyne and Cooley Godward Kronish LLP served as Replidyne's legal counsel. Citi acted as financial advisor to Cardiovascular Systems, Inc. and Fredrikson & Byron P.A. served as CSI's legal counsel.

About Cardiovascular Systems, Inc.

CSI is a medical device company focused on developing and commercializing intervent
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Replidyne Announces Second Quarter 2008 Results From Operations
2. Replidyne Terminates Faropenem Agreements
3. Replidyne to Report First Quarter 2008 Earnings
4. Replidyne Announces 2007 Fourth Quarter and Full Year Results
5. Replidyne to Report 2007 Fourth Quarter and Year-End Earnings
6. Replidyne to Announce Third Quarter 2007 Earnings
7. Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
8. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
9. CorMatrix Cardiovascular to Present Data on Its Next Generation ECM Technology(TM) at Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington, D.C.
10. Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm
11. Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During Live Case at the Paris Cardiovascular Interventions Course (Francophone) 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Pomerantz LLP is investigating claims on behalf of investors ... IPXL).  Such investors are advised to contact Robert ... ext. 237. The investigation concerns whether Impax ... Sections 10(b) and 20(a) of the Securities Exchange Act ... Impax Laboratories, Inc. (the "Company") issued a press release ...
(Date:7/29/2014)... July 29, 2014  Discovery Laboratories, Inc. (Nasdaq: ... a new standard of respiratory critical care, will report ... 5, 2014 before the open of the U.S. ... host a live teleconference and webcast at 9:00 a.m. ... call, Discovery Labs, management will discuss the 2014 ...
(Date:7/29/2014)... 2014  Cannabis Science, Inc. (OTC: CBIS), a ... and related consulting, applauds the Editorial Board of ... position in opposition to current federal law on ... The New York Times also announces a series ... the issue called "High Time:  An Editorial Series ...
(Date:7/29/2014)... July 29, 2014 July 29, ... pioneer in the biotechnology industry, announced that it ... Securities, Inc. to explore financing opportunities that build ... a breakthrough vaccine platform with the potential to ... company exclusively licensed the well-established LAMP platform from ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3
... second, one heartbeat. That,s what is needed for a ... the source in the heart of a dangerous cardiac arrhythmia ... beating of the heart, which, if ignored, can lead to ... yearly in the United States alone. The technique, developed ...
... the central region of ,macromolecules such as chlorophyll and ... that determines their specific function. The importance of these ... their "ease of transfer ,electrons from one region to ... Nanomaterials and Nanotechnology Research Center (a joint research center ...
... published today in the Journal of Urology, ... (degarelix) a gonadotropin-releasing hormone therapy (GnRH) for advanced ... study (CS21A) was an open-label extension of the pivotal ... was shown to be non-inferior to leuprolide in reducing ...
Cached Biology Technology:Dangerous arrhythmia analyzed in a heartbeat 2Dangerous arrhythmia analyzed in a heartbeat 3Dangerous arrhythmia analyzed in a heartbeat 4The quantum tunneling effect leads electron transport in porphyrins 2New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 2New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 3New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 4New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 5New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 6
(Date:7/29/2014)... 29 JULY 2014 With thirty days to go ... the FEBS-EMBO 2014 Conference are well underway. The event, ... Societies (FEBS), EMBO, and the French Society for Biochemistry ... 30 August to Thursday, 4 September at the Palais ... Conference is the largest meeting for the life sciences ...
(Date:7/29/2014)... breaking new book that brings together two of the ... the profile of insect fossils through stunning photographs and ... and James E Jepson, details the incredible preservation and ... the scene for what these remarkable fossils can tell ... the future of our planet. Like the mosquito in ...
(Date:7/29/2014)... Many different types of cell, including sperm, bacteria ... as flagella. These protrusions, about one-hundredth of a ... move through fluid. Similar, shorter structures called cilia ... where they perform roles such as moving liquids ... are remarkably versatile: they transport mucus and expel ...
Breaking Biology News(10 mins):Counting down to FEBS-EMBO 2014 in Paris, France 2Unique images bring fossil insects back to life 2Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3
... Mich.---It,s "Waterworld" snail style: Ocean-dwelling snails that spend most ... of mucus bubbles. Scientists have known about ... wondered how the rafting habit evolved. What, exactly, were ... Michigan graduate student Celia Churchill and coauthors believe they,ve ...
... Oral Squamous Cell Carcinoma (OSCC) is responsible for nearly a ... of the leading causes of cancer death - largely due ... recurrence of the disease. New research published in BioMed Central,s ... four-gene signature may accurately predict which patients are at higher ...
... at the University of California, San Diego School of Medicine ... of sugar molecule boosted disease protection in early hominids, and ... genus Homo . The findings, published in this ... National Academy of Sciences , are among the first evidence ...
Cached Biology News:In bubble-rafting snails, the eggs came first 2In bubble-rafting snails, the eggs came first 3In bubble-rafting snails, the eggs came first 4Sexual selection by sugar molecule helped determine human origins 2Sexual selection by sugar molecule helped determine human origins 3
... ion trap mass spectrometer enables high-throughput solutions ... LXQ linear ion trap mass spectrometer is ... delivering the fast cycle time and increased ... at an attractive price. The combination ...
... SYBR Safe DNA gel stain was developed specifically ... ethidium bromide for staining DNA in agarose or ... less mutagenic than ethidium bromide but SYBR Safe ... ethidium bromide. SYBR Safe stain comes as a ...
... some the things youll be telling others after ... by Erica Golemis, One look at the table ... topics in protein interaction will tell you immediately ... a part of your personal protein chemistry library. ...
... gel stain has bright fluorescence when bound to ... ideal for detecting dsDNA in gels using laser ... I nucleic gel acid stain has also ... and bandshift assays. One mL stains 100 minigels. ...
Biology Products: